跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Top Karina Anne Marie
Professor
Dalhousie University
,
Decision Sciences
电子邮件
TK936353
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=57211936353
h-index
h10-index
h5-index
1710
引用
22
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
1342
引用
20
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
555
引用
11
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
2005
2023
每年的科研成果
综述
指纹
网络
科研成果
(81)
新闻 / 媒体
(97)
相似简介
(6)
指纹
深入其中 Top Karina Anne Marie 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
Acute Lymphoblastic Leukemia
10%
Adverse Event
91%
Case Definition
35%
Clinical Trial
26%
Cohort Analysis
22%
Contraindication
16%
COVID-19
38%
COVID-19 Vaccination
12%
COVID-19 Vaccine
27%
Diphtheria
24%
Diphtheria Pertussis Tetanus Vaccine
13%
Disease
40%
Disease Severity
12%
Epileptic Seizure
23%
Gene Linkage
10%
Haemophilus Influenza Type B Infection
10%
Headache
11%
Health Care Provider
13%
Health Outcomes
10%
Infection
55%
Influenza A
10%
Influenza Vaccination
20%
Influenza Vaccine
48%
Kawasaki Disease
21%
Logistic Regression Analysis
13%
Malignant Neoplasm
10%
Measles
11%
Mumps
11%
Newborn Infection
10%
Odds Ratio
31%
Oncology
10%
Pediatric Hematology
10%
Pediatrician
12%
Pediatrics
49%
Pertussis
28%
Pertussis Vaccine
12%
Poliomyelitis Vaccine
10%
Public Health
32%
Recurrent Disease
23%
Revaccination
21%
Rubella
11%
Seasonal Influenza
17%
Serositis
10%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Symptom
12%
Tetanus
24%
Transplantation
10%
University Student
10%
Vaccine
49%
Virtual Patient
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
10%
Adverse Event
100%
Agrotis
12%
Antibiotic Prophylaxis
7%
Antiinfective Agent
10%
Biological Product
10%
Cefprozil
7%
Chemotherapy
6%
Chickenpox
10%
Chickenpox Vaccine
11%
Clinical Trial
33%
Cohort Study
32%
COVID-19 Vaccine
27%
Diphtheria
6%
Diphtheria Pertussis Tetanus Vaccine
12%
Disease
52%
Disease Severity
12%
Headache
11%
Immunogenicity
12%
Inactivated Vaccine
21%
Infection
51%
Inflammation
23%
Influenza A
10%
Influenza B
10%
Influenza Vaccine
32%
Injection Site Reaction
5%
Interleukin 1 Receptor
10%
Live Attenuated Influenza Vaccine
6%
Monoclonal Antibody
10%
mRNA Vaccine
9%
Mucocutaneous Lymph Node Syndrome
21%
Myocarditis
10%
Observational Study
6%
Off-Label Use
10%
Pandemic
10%
Paresthesia
10%
Pericarditis
10%
Pertussis
19%
Pertussis Vaccine
7%
Pharmacovigilance
12%
Recurrent Disease
23%
Retrospective Study
10%
Rubella
6%
SARS Coronavirus
11%
Seasonal Influenza
25%
Symptom
9%
Syndrome
10%
Tetanus
6%
Vaccination Policy
72%
Vaccine
64%
Keyphrases
Active Surveillance
22%
Adjusted Odds Ratio
13%
Adverse Events Following Immunization
27%
Anovaginal
10%
Antenatal Exposure
10%
Canada
17%
Child Hospitalized
11%
Childhood Epilepsy
21%
Children with Cancer
10%
Climate Change
10%
Confidence Interval
23%
Emergency Department Visits
10%
Epilepsy
15%
Guillain-Barré Syndrome
10%
Haemophilus Influenzae Type b
12%
Health Events
13%
Hospitalization
31%
Immunization
57%
Immunization Monitoring
38%
Immunization Practices
10%
Immunization Programs
13%
Immunization Surveillance
15%
Influenza
17%
Interval Analysis
10%
Kawasaki Disease
21%
Live Vaccine
18%
Meta-analysis
10%
Monitoring Program
38%
Multisystem Inflammatory Syndrome in Adults (MIS-A)
10%
Network Studies
21%
Older children
10%
Pediatric Hospital
11%
Pediatric Hospitalization
13%
Pediatric Residents
10%
Pediatric Transplantation
21%
Pregnant Women
12%
Risk Interval
10%
Sars-cov-2 Infection
10%
Solid Organ Transplant
10%
Solid Organ Transplant Recipients
10%
Stakeholder Approach
10%
Systematic Meta-analysis
10%
University Setting
10%
Vaccination
16%
Vaccination Program
12%
Vaccine Program
21%
Vaccine Regulation
10%
Vaccine Use
10%
Vaccinees
12%
Virtual Patient
10%
